Skip to content
Methylergonovine
Methergine (methylergonovine) is a small molecule pharmaceutical. Methylergonovine was first approved as Methergine on 1982-01-01. It is used to treat postpartum hemorrhage in the USA. It is known to target 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 1F, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 2B.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Methergine (generic drugs available since 2008-11-24)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methylergonovine maleate
Tradename
Company
Number
Date
Products
METHERGINEEdison PharmaceuticalsN-006035 RX1982-01-01
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
methergineANDA2020-01-21
methylergonovine maleateANDA2023-02-17
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
postpartum hemorrhage—D006473O72
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G02: Other gynecologicals in atc
— G02A: Uterotonics
— G02AB: Ergot alkaloid oxytocics
— G02AB01: Methylergometrine
— G02AC: Ergot alkaloids and oxytocin incl. analogues, in combination
— G02AC01: Methylergometrine and oxytocin
HCPCS
Code
Description
J2210
Injection, methylergonovine maleate, up to 0.2 mg
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Uterine inertiaD014593EFO_1001863O62.21——2—3
Postpartum hemorrhageD006473O721——1—2
HemorrhageD006470MP_0001914R58———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cesarean sectionD0025851————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
EndometritisD004716EFO_1001312————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMETHYLERGONOVINE
INNmethylergometrine
Description
(6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide is an ergoline alkaloid.
Classification
Small molecule
Drug classergot alkaloid deriviatives; vinca alkaloids
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
Identifiers
PDB6DRY
CAS-ID113-42-8
RxCUI6883
ChEMBL IDCHEMBL1201356
ChEBI ID—
PubChem CID8226
DrugBankDB00353
UNII IDW53L6FE61V (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
HTR1E
HTR1E
HTR1F
HTR1F
HTR2C
HTR2C
HTR2A
HTR2A
HTR2B
HTR2B
Organism
Homo sapiens
Gene name
HTR1E
Gene synonyms
NCBI Gene ID
3354
Protein name
5-hydroxytryptamine receptor 1E
Protein synonyms
5-HT-1E, 5-hydroxytryptamine (serotonin) receptor 1E, G protein-coupled, S31, Serotonin receptor 1E
Uniprot ID
Q9P1Y1
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 839 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
695 adverse events reported
View more details